ArticleScientific reports2026
SBA-15-supported copper(II)-2-hydrazinopyridine complex as an efficient reusable catalyst for the selective monoarylation of ammonia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A novel Cu(II)-based heterogeneous catalyst, SBA-15@bis(Py-2-NHNH2)-Cu(II), was prepared via sequential functionalization of SBA-15 with APTES, cyanuric acid, and 2-hydrazinopyridine, followed by Cu(OAc)2 complexation. The catalyst was thoroughly characterized by FT-IR, solid-state13C NMR, TGA, BET, XPS, and EDAX, confirming successful ligand grafting, Cu(II) coordination, and structural integrity. Under optimized conditions in DMSO, the catalyst efficiently promoted ammonia monoarylation with a wide range of aryl halides. It exhibited negligible activity loss and minimal copper leaching (< 0.2%) in the first run and maintained its performance over five consecutive cycles. Hot filtration experiments further confirmed its heterogeneous nature and sustained stability. Post-catalytic characterization by FT-IR and EDAX verified that the catalyst retained its structure and active metal centers. Overall, these results demonstrate that SBA-15@bis(Py-2-NHNH2)-Cu(II) is a robust, recyclable, and sustainable catalyst, providing an effective alternative to precious metals for C-N bond formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.